Research progress of tumor autoantibodies and CT artificial intelligence in early diagnosis of NSCLC
10.11855/j.issn.0577-7402.0994.2024.0104
- VernacularTitle:肿瘤自身抗体及CT人工智能在NSCLC早期诊断中的应用研究进展
- Author:
Jing WANG
1
;
Cheng-Kai ZHAI
Author Information
1. 新乡医学院第五临床学院/新乡市第一人民医院呼吸与危重症医学科,河南新乡 453000
- Keywords:
non-small-cell lung carcinoma;
autoantibodies;
artificial intelligence;
pulmonary nodules;
early diagnosis
- From:
Medical Journal of Chinese People's Liberation Army
2024;49(7):848-854
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer(NSCLC)is one of the most prevalent and deadly malignant tumors in the world.In recent years,artificial intelligence(AI)in computed tomography(CT)has harnessed the power of big data to automatically extract and learn imaging features,thereby assisting radiologists in reducing the workload and missed diagnosis rate of pulmonary nodules.An ELISA kit for detecting seven lung cancer autoantibodies(p53,SOX2,PGP9.5,CAGE,MAGE-A1,GAGE7,and GBU4-5)has been clinically implemented in China,showing high specificity in the early screening of NSCLC.Additionally,other liquid biopsy techniques such as circulating tumor DNA(ctDNA)methylation markers are also continually being explored.However,existing methods for the early diagnosis of lung cancer all have their limitations,and optimizing their combination or establishing diagnostic models has become a trend.This review summarizes the research progress and value of the seven lung cancer autoantibodies and CT AI in the early diagnosis of NSCLC,with the aim of providing a reference for their combined use in the early diagnosis of lung cancer in Chinese population.
